<h4>Purpose</h4>To investigate the expression patterns of Human Epidermal Growth Factor Receptor 2 (HER2) and their clinicopathological associations across the full spectrum (negative, low, and overexpression) in a large cohort of Chinese urothelial carcinoma (UC) patients.<h4>Materials and methods</h4>A multicenter registry study (April 2023-March 2024) across eight Chinese tertiary hospitals included 1054 UC patients. This evidence concerns the gene ERBB2 and urothelial carcinoma.